Kyverna Therapeutics, a clinical-stage biopharmaceutical company, announced the pricing of a $100 million public offering of common stock.
The offering consists of 13,333,333 shares priced at $7.50 per share.
The underwritten public offering is expected to close on or about December 18, 2025.
Public Offering
Kyverna Therapeutics is offering 13,333,333 shares of common stock at $7.50 per share, aiming to raise approximately $100 million.
Underwriters
J.P. Morgan, Leerink Partners, Morgan Stanley, and Wells Fargo Securities are acting as joint book-running managers for the offering.
Shelf Registration
The offering is made under an effective shelf registration statement on Form S-3 (File No. 333-286180) filed with the SEC in March 2025.
- Kyverna Therapeutics aims to secure funds for its ongoing clinical-stage developments in autoimmune cell therapies.
- The successful offering signifies investor confidence in Kyverna's potential in the biopharmaceutical industry.
The pricing of the public offering marks a significant step for Kyverna Therapeutics in funding its innovative therapies and advancing in the biopharmaceutical sector.